Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Randomized, Double-Blind, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of TI-0010 Vaccine to Prevent COVID-19 Caused by SARS-CoV-2 in Healthy Adults Aged 18-59 Years

NCT06205524 is registered in ClinicalTrials.gov with National Drug Clinical Trial Institute of the Second Affiliated Hospital of Bengbu Medical College as lead sponsor.

NCT NCT06205524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06205524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Randomized, Double-Blind, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of TI-0010 Vaccine to Prevent COVID-19 Caused by SARS-CoV-2 in Healthy Adults Aged 18-59 Years
Lead sponsor
National Drug Clinical Trial Institute of the Second Affiliated Hospital of Bengbu Medical College
Phase
Phase 1
Overall status
Unknown status
Start date
July 10, 2023
Completion date
February 1, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 immunisation